Modeling opportunities in comparative oncology for drug development

ILAR Journal

Volumn 51, Issue 3, 2010, Pages 214-220

  Gordon, Ira K ^a   Khanna, Chand ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Comparative oncology; Dog; Drug development; Preclinical model

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT;

ANIMAL; DISEASE MODEL; DOG; DRUG DEVELOPMENT; HUMAN; METHODOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOGS; DRUG DISCOVERY; HUMANS; NEOPLASMS;

EID: 79953151733     PISSN: 10842020     EISSN: None     Source Type: Journal    
DOI: 10.1093/ilar.51.3.214     Document Type: Article

References (39)

1. Abdulkadir SA, Kim J. 2005. Genetically engineered murine models of prostate cancer: Insights into mechanisms of tumorigenesis and potential utility. Future Oncol 1:351-360.
2. APPMA [American Pet Products Manufacturers Association]. 2005. 2005-2006 APPMA National Pet Owners Survey. Greenwich CT: APPMA.
3. Becher OJ, Holland EC. 2006. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66:3355-3358, discussion 3358-3359.
4. Breen M. 2009. Update on genomics in veterinary oncology. Top Companion Anim Med 24:113-121.
5. Breen M, Modiano JF. 2008. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans: Man and his best friend share more than companionship. Chromosome Res 16: 145-154.
6. Bronson RT. 1982. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 43:2057-2059.
7. Cespedes MV, Casanova I, Parreno M, Mangues R. 2006. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 8:318-329.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 2009. New response evaluation criteria in solid tumours: Revised RECIST guideline (v. 1.1). Eur J Cancer 45:228-247.
9. Felsburg PJ. 2002. Overview of immune system development in the dog: Comparison with humans. Hum Exp Toxicol 21:487-492.
10. Forrest LJ, Mackie TR, Ruchala K, Turek M, Kapatoes J, Jaradat H, Hui S, Balog J, Vail DM, Mehta MP. 2004. The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verifi cation purposes. Int J Radiat Oncol Biol Phys 60:1639-1644.
11. Goodstadt L, Ponting CP. 2006. Phylogenetic reconstruction of orthology, paralogy, and conserved synteny for dog and human. PLoS Comput Biol 2:e133.
12. Gutierrez ME, Kummar S, Giaccone G. 2009. Next generation oncology drug development: Opportunities and challenges. Nat Rev Clin Oncol 6:259-265.
13. Hansen K, Khanna C. 2004. Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development. Eur J Cancer 40:858-880.
14. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. 2001. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431.
15. Kelland LR. 2004. Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827-836.
16. Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. 2009. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res 26:5671-5677.
17. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. 1994. Specifi c association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015.
18. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH. 2008. Phase 0 clinical trials: Conceptions and misconceptions. Cancer J 14:133-137.
19. Liao AT, McMahon M, London C. 2005. Characterization, expression and function of c-Met in canine spontaneous cancers. Vet Comp Onc 3: 61-72.
20. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. 2003. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 9:2755-2768.
21. Neyt JG, Buckwalter JA, Carroll NC. 1998. Use of animal models in musculoskeletal research. Iowa Orthop J 18:118-123.
22. Olive KP, Tuveson DA. 2006. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12:5277-5287.
23. Paoloni M, Khanna C. 2008. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8:147-156.
24. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK. 2009. Launching a novel preclinical infrastructure: Comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972.
25. Peterson JK, Houghton PJ. 2004. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837-844.
26. Porrello A, Cardelli P, Spugnini EP. 2006. Oncology of companion animals as a model for humans: An overview of tumor histotypes. J Exp Clin Cancer Res 25:97-105.
27. Prowse KR, Greider CW. 1995. Developmental and tissue-specifi c regulation of mouse telomerase and telomere length. Proc Natl Acad Sci U S A 92:4818-4822.
28. Rangarajan A, Weinberg RA. 2003. Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer 3:952-959.
29. Rygaard J, Povlsen CO. 1969. Heterotransplantation of a human malignant tumour to "nude" mice. Acta Pathol Microbiol Scand 77:758-760.
30. Sausville EA, Burger AM. 2006. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351-3354, discussion 3354.
31. Schuh JC. 2004. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 32 Suppl 1:53-66.
32. Sharpless NE, Depinho RA. 2006. The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754.
33. Talmadge JE, Singh RK, Fidler IJ, Raz A. 2007. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170: 793-804.
34. Teicher BA. 2009. In vivo/ex vivo and in situ assays used in cancer research: A brief review. Toxicol Pathol 37:114-122.
35. Tomaszewski JE. 2004. Multi-species toxicology approaches for oncology drugs: The US perspective. Eur J Cancer 40:907-913.
36. Vail DM, MacEwen EG. 2000. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18:781-792.
37. Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. 2009. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res 15:3503-3510.
38. Voskoglou-Nomikos T, Pater JL, Seymour L. 2003. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9:4227-4239.
39. Woodhouse DL. 1947. Chemotherapy investigations in cancer; with reference to the infl uence of certain organic dibasic acids, diamino compounds and nitro compounds on tumors in mice. Cancer Res 7:398-401.